Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Nephrol Dial Transplant. 2013 Jul;28(7):1908-14. doi: 10.1093/ndt/gfs603. Epub 2013 Jan 24.
Encapsulating peritoneal sclerosis (EPS) is a rare complication of peritoneal dialysis (PD) that is associated with significant morbidity and mortality in adults. There are scarce data for children. We performed a 10-year survey to determine the prevalence, risk factors and outcome for EPS in children.
Chronic PD patients in 14 dialysis units participating in the European Paediatric Dialysis Working Group between January 2001 and December 2010 were included in this study.
Twenty-two cases of EPS were reported (prevalence 1.5%; 8.7 per 1000 patient-years on PD). Median PD vintage was 5.9 (1.6-10.2) in EPS and 1.7 (0.7-7.7) years in the remainder of the PD population (P<0.0001). EPS patients had a significantly higher peritonitis rate than non-EPS patients (P=0.2). EPS was diagnosed while the child was on PD in 17 (77%), after conversion to haemodialysis (HD) in 3 and after transplantation in 2. Fifteen of 17 (88%) developed ultrafiltration (UF) failure. The median interval between UF failure and presentation with bowel obstruction was 2.8 (0.02-5.8) months. Twenty (91%) had clinical and radiological signs of bowel obstruction. Enterolysis was performed in 14 and 19 received immunosuppression or tamoxifen. Nine required parenteral nutrition. At final follow-up 4.8 (1.3-8.7) years after EPS diagnosis, 3 patients died, 11 had a functioning transplant and 8 were on HD.
The prevalence of EPS in European children on PD is comparable with that of adult PD patients, but mortality from paediatric EPS is significantly lower. A high index of suspicion is required for the diagnosis of EPS in children with longer dialysis duration, a high peritonitis rate and UF failure.
包裹性腹膜硬化症(EPS)是腹膜透析(PD)的一种罕见并发症,会导致成年人出现严重的发病率和死亡率。儿童的数据很少。我们进行了一项为期 10 年的调查,以确定儿童中 EPS 的患病率、危险因素和结局。
本研究纳入了 2001 年 1 月至 2010 年 12 月期间参与欧洲儿科透析工作组的 14 个透析单位的慢性 PD 患者。
报告了 22 例 EPS 病例(患病率为 1.5%;PD 患者每 1000 人年中有 8.7 例)。EPS 患者的 PD 治疗时间中位数为 5.9(1.6-10.2)年,而 PD 人群中其余患者的 PD 治疗时间中位数为 1.7(0.7-7.7)年(P<0.0001)。EPS 患者腹膜炎发生率显著高于非-EPS 患者(P=0.2)。17 例(77%)患者在 PD 期间诊断为 EPS,3 例在转为血液透析(HD)后诊断,2 例在移植后诊断。15 例(88%)出现超滤(UF)失败。UF 失败和出现肠梗阻之间的中位时间间隔为 2.8(0.02-5.8)个月。20 例(91%)有肠梗阻的临床和影像学征象。14 例行肠松解术,19 例接受免疫抑制或他莫昔芬治疗。9 例需要肠外营养。在 EPS 诊断后 4.8(1.3-8.7)年的最终随访时,3 例患者死亡,11 例患者有功能移植,8 例患者在接受 HD 治疗。
欧洲 PD 儿童中 EPS 的患病率与成人 PD 患者相似,但儿科 EPS 的死亡率明显较低。对于透析时间较长、腹膜炎发生率较高和 UF 失败的儿童,需要高度怀疑 EPS 的诊断。